|
|
 |
| NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for: Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions. Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia.
|
|
|
|
|
| Novo Nordisk understands knowledge is power. We’re here to share it. |
| Learn about the importance of self-advocacy and how to take charge of your care. |
| If you’re living with a rare bleeding disorder or suspect you may have one, understanding your condition and how to advocate for yourself can make all the difference. |
Our Novo Nordisk Rare Blood Community Liaisons (RBCLs) have been immersed in this community for years and are eager to support you, no matter where you are on your journey.
- Have questions about identifying bleeds?
- Interested in learning about NovoSeven® RT?
- Want tips on how to self-advocate to your doctor?
- Need to connect with someone who really gets what you’re going through?
Let’s talk about what matters to you—and how we can help.
|
|
|
|
| Keep scrolling to learn more about how to contact an RBCL |
 |
|
|
Important Safety Information for NovoSeven® RT?
|
|
What is the most important information I should know about NovoSeven® RT?
|
|
NovoSeven® RT may cause serious side effects, including:
|
| • |
Serious blood clots that form in veins and arteries with the use of
NovoSeven® RT have been reported
|
|
| • |
Your healthcare provider should discuss the risks and explain the signs and symptoms
of blood clots to you. Some signs of a blood clot may include pain, swelling,
warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or
sudden severe headache and/or loss of consciousness or function
|
|
| • |
Your healthcare provider should monitor you for blood clots during treatment with
NovoSeven® RT
|
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
|
| |
|
| Get connected with your Novo Nordisk Rare Blood Community Liaison (RBCL) |
| Life with a bleeding disorder can bring challenges. Our RBCLs are experienced and ready to provide you with one-on-one support, including: |
 |
Information about NovoSeven® RT |
 |
Lifestyle education and resources |
 |
Where to find local events |
 |
Tools to help you manage your bleeding disorder |
|
|
|
|
|
|
|
 |
| Stay in the know |
| Be the first to get important updates about NovoSeven® RT, including patient support programs, insurance information through NovoCare®, and more. |
|
|
|
| What is NovoSeven® RT? |
| NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for: |
| • |
Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions |
|
| • |
Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia |
|
| Important Safety Information (cont’d) |
|
What is the most important information I should know about NovoSeven® RT? (cont’d)
|
|
NovoSeven® RT may cause serious side effects, including: (cont’d)
|
| • |
You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness
|
|
|
What should I tell my healthcare provider before using NovoSeven® RT?
|
| • |
Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
|
| |
| ◦ |
congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates) |
| ◦ |
are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding |
| ◦ |
history of heart or blood vessel diseases |
|
|
| • |
Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies
|
|
|
What are the possible side effects of NovoSeven® RT?
|
| • |
The most common and serious side effects are blood clots
|
|
| • |
Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction
|
|
| Please click here for Prescribing Information. |
|
NovoSeven® RT is a prescription medication.
|
|
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
|
|
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500. |
|
NovoSeven® is a registered trademark of Novo Nordisk Health Care AG. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved. US25NSVN00046 September 2025 |
 |
|
|
|